UnitedHealth Group’s recent quarterly results highlighted its progress in controlling medical cost trends that have pressured the industry over the past two years. The company reported earnings per share of $2.92, exceeding analyst consensus by $0.05, on revenue of $113.16 billion. Revenue rose 12.2% year-over-year, driven by growth in both its UnitedHealthcare benefit plans and Optum health services divisions. Return on equity stood at 19.23%, while the net margin was 4.04%. Executives emphasized that specialty drug spending moderated sequentially, contributing to a year-to-date medical cost ratio improvement of 40 basis points. Investors will watch whether these trends persist when the next insurer follows UnitedHealth as the first major health plan to report each quarter.

In a filing disclosed January 15, Representative Julie Johnson of Texas reported the sale of between $1,001 and $15,000 in UnitedHealth Group shares on December 18. The transaction occurred in her Chase Brokerage Account (3935), as she continues to adjust her portfolio following similar sales in companies across multiple sectors. While the disclosed range limits precise valuation, this marks the first sale of her holdings in the health insurer since taking office in January 2025. Representative Johnson, who serves Texas’s 32nd District, completed her law degree in 1991 and previously practiced as an attorney.

UnitedHealth Group declared a quarterly dividend of $2.21 per share, payable December 16 to shareholders of record December 8, reflecting an annualized payout of $8.84 and a dividend yield of 2.7%. The payout ratio is approximately 46.1%. On the institutional front, CFC Planning Co. added 12,764 new shares during the third quarter, representing roughly 3.6% of its portfolio. North Capital Inc. raised its position by 16.2%, Sunflower Bank N.A. by 1.5%, and Axis Wealth Partners LLC by 1.7% over the same period. Overall, institutional investors now hold nearly 88% of outstanding shares, underscoring confidence from large asset managers despite ongoing regulatory and cost pressures.